305 related articles for article (PubMed ID: 30426652)
1. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
2. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
4. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
[TBL] [Abstract][Full Text] [Related]
6. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.
Ranieri L; Contero C; Peral ML; Calabuig I; Zapater P; Andres M
Arthritis Res Ther; 2018 Mar; 20(1):53. PubMed ID: 29566736
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
8. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
9. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Singh JA; Yang S; Saag KG
J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
[TBL] [Abstract][Full Text] [Related]
12. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
13. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Toprover M; Crittenden DB; Modjinou DV; Oh C; Krasnokutsky S; Fisher MC; Keenan RT; Pillinger MH
Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):87-91. PubMed ID: 31140959
[TBL] [Abstract][Full Text] [Related]
15. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
16. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
17. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Rheumatology (Oxford); 2018 Dec; 57(12):2183-2189. PubMed ID: 30107437
[TBL] [Abstract][Full Text] [Related]
18. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
[TBL] [Abstract][Full Text] [Related]
20. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
